Twist Bioscience (NASDAQ:TWST) Shares Down 4.4%

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report)'s share price fell 4.4% during trading on Tuesday . The company traded as low as $27.90 and last traded at $27.95. 98,884 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 907,806 shares. The stock had previously closed at $29.24.

Analyst Ratings Changes

A number of research firms have commented on TWST. Barclays reduced their target price on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a report on Wednesday, April 10th. The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and raised their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Scotiabank raised their price target on Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 5th.

Twist Bioscience Trading Down 2.2 %

The stock has a market capitalization of $1.65 billion, a PE ratio of -7.93 and a beta of 1.62. The stock has a 50 day moving average price of $35.98 and a 200-day moving average price of $29.95.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. During the same period in the previous year, the business earned ($0.74) earnings per share. Twist Bioscience's quarterly revenue was up 31.8% compared to the same quarter last year. Research analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the business's stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company's stock, valued at $2,244,631.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Robert Chess sold 4,110 shares of the company's stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the transaction, the director now owns 64,169 shares of the company's stock, valued at $2,244,631.62. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 1,128 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares in the company, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,037 shares of company stock valued at $384,092. 3.92% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

A number of large investors have recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in shares of Twist Bioscience by 3.3% in the third quarter. Royal Bank of Canada now owns 9,025 shares of the company's stock valued at $318,000 after purchasing an additional 291 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Twist Bioscience by 101.3% in the second quarter. Captrust Financial Advisors now owns 759 shares of the company's stock valued at $27,000 after purchasing an additional 382 shares during the period. D.A. Davidson & CO. boosted its holdings in shares of Twist Bioscience by 3.4% in the fourth quarter. D.A. Davidson & CO. now owns 16,774 shares of the company's stock valued at $618,000 after purchasing an additional 554 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Twist Bioscience by 16.0% in the first quarter. Ameritas Investment Partners Inc. now owns 4,293 shares of the company's stock valued at $212,000 after purchasing an additional 591 shares during the period. Finally, US Bancorp DE lifted its holdings in Twist Bioscience by 11.8% during the first quarter. US Bancorp DE now owns 5,942 shares of the company's stock worth $295,000 after buying an additional 626 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.